 BOSTON, July 30, 2020 GLOBE NEWSWIRE -- Albireo Pharma, Inc. Nasdaq: ALBO, a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT. The live webcast of the presentation will be accessible from the Media Investors page of Albireos website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events Presentations section of the Media Investors page of Albireos website for at least two weeks following the event.About Albireo Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in progressive familial intrahepatic cholestasis PFIC and biliary atresia, with a third Phase 3 trial being planned in Alagille syndrome. Albireos clinical pipeline also includes two Phase 2 product candidates. Elobixibat is in Phase 2 development in NAFLD and NASH. Approved in Japan for the treatment of chronic constipation, elobixibat is the first ileal bile acid transporter IBAT inhibitor approved anywhere in the world.Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Mass., and its key operating subsidiary is located in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. For more information on Albireo, please visit Contact: Hans Vitzthum, LifeSci Advisors, LLC., 212-915-2568 Media Contact: Claire LaCagnina, 6 Degrees, 315-765-1462, 